
Full profile: /officials/V000138
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Currently in
Previously
This bill would expand access to sickle cell disease treatments and support services for patients and families affected by the condition. It likely aims to increase funding for research, improve screening and care programs, and help reduce the financial burden on families dealing with this serious inherited blood disorder. The legislation would affect sickle cell patients, their families, healthcare providers, and medical research institutions.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8067 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8067 To direct the Secretary of Health and Human Services to carry out a program under which the Secretary will collect data with respect to sickle cell disease in the United States, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 24, 2026 Mr. Vindman introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To direct the Secretary of Health and Human Services to carry out a program under which the Secretary will collect data with respect to sickle cell disease in the United States, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Candis King Hope for Sickle Cell Families Act''. SEC. 2. SICKLE CELL DATA COLLECTION PROGRAM. (a) In General.--The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (in this Act referred to as the ``Secretary''), shall carry out a program under which the Secretary will collect data on the incidence and prevalence of sickle cell disease in the United States, to be known as the Sickle Cell Data Collection program, through awarding grants to States for the following purposes: (1) To collect and maintain data on sickle cell disease to gain a better understanding of the incidence and prevalence of sickle cell disease in the United States, the demographics of individuals in the United States living with sickle cell disease, and the healthcare utilization patterns of individuals in the United States living with sickle cell disease. (2) To collaborate with other entities who received grants under the Sickle Cell Data Collection program of the Centers for Disease Control and Prevention (as in effect on the day before the date of the enactment of this Act) and the Centers for Disease Control and Prevention for purposes of increasing the standardization of methods for sickle cell disease surveillance. (b) Authorization of Appropriations.--There are authorized to be appropriated to carry out the program referred to in subsection (a), $10,000,000 for each of fiscal years 2027 through 2031. SEC. 3. DIVISION OF BLOOD DISORDERS AND PUBLIC HEALTH GENOMICS. (a) In General.--The Secretary of Health and Human Services shall reinstate any covered employee of the Division of Blood Disorders and Public Health Genomics of the Centers for Disease Control and Prevention. (b) Covered Employee Defined.--In this section, the term ``covered employee'' means an employee of the Division of Blood Disorders and Public Health Genomics of the Centers for Disease Control and Prevention who was removed on or after January 1, 2025, under any agency action (including any reduction in force conducted pursuant to subchapter I of chapter 35 of title 5, United States Code or any agency reorganization) that provides for the removal of 3 percent or more of the total number of employees at such Division within a 60-day period. <all>
Bills by the same sponsor or covering overlapping subjects.